

Operational Goals for 2007/2008

Adding Value to Co-X-Gene technology

- Further advance product development of HIV-immunotherapeutic vaccine VIR201 in South Africa
- Transgene license and their product development

VIR201 Product Development

Virax lead product is VIR201 to treat HIV/AIDS

- One of the most advanced HIV/AIDS immunotherapeutic in human trials.
- Completed Phase I and Phase IIa trials with positive results.
- Protected by Patents – to 2019.

South African Trial

- Regulatory Approval obtained August 2008 for Phase I/IIa trial.
- Trial funded by corporate donors with South African interests.

Overview of Southern African Trial of VIR201

Overview

- Corporate Donor Funding mechanism
- Utility of HIV Immunotherapeutic Vaccine in Southern Africa
- Study Design
- Aims
- Status

Donors


- Currently all Donors are from the Mining Industry:
 - Anvil Mining
 - ARM
 - Assmang
 - BHP Billiton
 - Gold Fields Mining
 - Harmony Gold Mining
 - Lonmin Plc
 - Mitsubishi
 - Nippon
 - Paladin Energy
 - Rio Tinto
 - Sumitomo
- Ongoing Fundraising

Therapeutic HIV Vaccines

Concept: Boost immunity to HIV in HIV infected individuals

- **Problems associated with antiretroviral treatment**
 - long term toxicities
 - risk of emergence of drug resistance
 - cost
 - patient adherence to drug schedule
- **Potential uses**
 - abrogate the need for sustained antiretroviral therapy
 - Lengthen time between primary infection and need to commence antiretroviral therapy.

Potential Application of VIR201 in Southern Africa




Trial Design and Aims of South African Clinical Trial of VIR201

- Up to 140 participants randomised to ensure minimum of 108 evaluable participants (72 VIR201: 36 Placebo)
- Measure safety, tolerability and immunogenicity in HIV-positive participants who are either naïve to antiretroviral treatment (ART) or are currently on ART.
- Comprehensive measurement of T-cell and humoral immune responses generated to Clade B and Clade C HIV virus
- Use of 10-15 fold higher dose of vaccine than used in Australian trials



Slide 7

Trial Clinics, Laboratories and Clinical Operations



Clinical trial sites:

1. Dr Orrell, Cape Town,
2. Dr Kelbe, Richards Bay
3. Dr Tempelman, Groblersdal
4. Prof Churchyard, Klerksdorp

Laboratories:

5. Aurum Institute (Prof Churchyard), Klerksdorp
6. CLS Joburg
7. Q-labs
8. CLS Durban
9. CLS Cape Town
10. NICD Joburg
11. TOGA Joburg

Clinical Operations:

12. Quintiles, Cape Town
13. Quintiles, Bloemfontein
14. Quintiles, Pretoria

South African Trial Project Status

- MCC Regulatory Approval – August 2008
- Four clinical sites
- Laboratory testing contracts being finalised
- Final stability testing of vaccine taking place at manufacturer to allow vaccine release
- Investigator meeting held - 20-21 October, Capetown
- First patient screening and vaccination planned for Q4 2008

Outlicensing of Co-X-Gene™ Technology

Licence to Transgene, a French immunotherapeutic company:

- TG4001 – about to commence Phase IIb trial – cancer product.
- TG4010 – completing Phase II trials – cancer product.

Virax-Transgene Sub-Licence

- Scope limited to TG4001 and TG4010 in North America.
- Payment to Virax to date – A\$2.2 million.
- Share of Transgene development milestone payments (up to US\$12 million).
- Royalty on North American sales.

Validation of Co-X-Gene™ technology (different delivery vector; MVA)

Value of license enhanced with Transgene's TG4001 exclusive global licensing deal with Roche for treatment of HPV related pathologies (April 2007)

Net present value of Virax-Transgene License – US\$9 Million (bio-dollars)